Posted in | News | Medical Robotics

AiM Medical Robotics Launches Prototype of Industry-First Robotics Platform, Receives Investment from the Sontag Innovation Fund

AiM Medical Robotics, a leading developer of MRI-compatible intraoperative robotics for neurosurgery, today announced the unveiling of a prototype of its industry-first robotics platform as well as the receipt of funding from the Sontag Innovation Fund, a wholly-owned venture subsidiary of The Sontag Foundation, one of the largest private funders of brain cancer research in the United States.

The Sontag Innovation Fund invests in early stage and innovative technologies with the potential to drive cures and improve the quality of life or life expectancy for brain cancer patients. The investment comes subsequent to the close of AiM's seed financing round, which was announced in March.

"The prototype is a testament to the progress that our company has made so far, bringing us closer to our goal of improving outcomes for patients undergoing neurosurgery and providing cost savings to hospitals by eliminating errors and reducing procedure times," said Bob Cathcart, CEO of AiM. "The Sontag Foundation's commitment to fund innovative advancements towards the treatment of brain tumors perfectly aligns with AiM's core values, and we look forward to a fruitful collaboration." 

"Dr. Pilitsis, Prof. Fischer, and the AiM team are developing a groundbreaking and innovative MRI-compatible robotics platform that has the potential to impact the lives of patients across neurological disorders," said Scott Davis, Ph.D., Senior Associate of the Sontag Innovation Fund. "We are encouraged by the team and this technology and hope the investment will attract additional external capital to improve the health status of brain cancer patients."


Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.